Building true partnerships with overseas labs
As she advances global health, LJI Professor Sujan Shresta takes on three new research projects to support equity for scientists in South and Southeast Asia
Leinco Technologies, Inc., and La Jolla Institute for Immunology announce license agreement to develop novel COVID-19 diagnostic tools
In addition to developing the antibodies for use in diagnostic applications based on N protein-specific antibodies, Leinco will make these antibodies commercially available as part of their extensive catalogue of research tools.
The story behind a vivid pancreas image
"To prevent and treat the disease, it is vital to understand how the immune cells attack the body's own insulin-producing beta cells"
Long days, bus rides and a high schooler’s bioinformatics breakthrough
San Diego high school student Jeffrey Wang spearheads LJI research project, receiving national recognition as Regeneron Science Talent Search finalist
COVID-19 research—a year later
5 takeaways from February's "Live from the Lab" webinar
Had Covid? You May Need Only One Dose of Vaccine, Study Suggests
People who have already been sick with Covid-19 should still be vaccinated, experts say, but they may experience intense side effects even after one dose.
Coronavirus mutations add urgency to vaccination effort as experts warn of long battle ahead
T cells can mount attacks against many SARS-CoV-2 targets—even on new virus variant
New LJI research gives detailed look at vulnerable sites on the novel coronavirus—beyond the receptor binding domain
LJI asthma researcher Jermaine Khumalo receives AAI Intersect Fellowship
New fellowship will support data science and immunology cross-training in two pioneering LJI labs
A closer look at T cells reveals big differences in mild vs. severe COVID-19 cases
New research highlights the enormous variability in how T cells respond to the deadly virus
Experts torn over changing vaccine doses to speed up lagging rollout
To speed inoculations, the U.S. plans to release all available vaccine doses and open access to anyone over 65. Others suggest straying from recommended doses or intentionally delaying boosters. The best way forward remains uncertain.